We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Kura Oncology Inc (KURA) USD0.0001

Sell:$18.76 Buy:$18.77 Change: $0.1 (0.53%)
NASDAQ:0.10%
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Sell:$18.76
Buy:$18.77
Change: $0.1 (0.53%)
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Sell:$18.76
Buy:$18.77
Change: $0.1 (0.53%)
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Contact details

Address:
12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO
92130
United States
Telephone:
+1 (858) 5008800
Website:
https://www.kuraoncology.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KURA
ISIN:
US50127T1097
Market cap:
$1.39 billion
Shares in issue:
76.18 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Troy Wilson
    Chairman of the Board, President, Chief Executive Officer
  • Kathleen Ford
    Chief Operating Officer
  • Stephen Dale
    Chief Medical Officer
  • Brian Powl
    Chief Commercial Officer
  • Teresa Bair
    Chief Legal Officer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.